Newsbenzinga
AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease
· Published
Article summary
AstraZeneca's Ultomiris cut proteinuria by 46.6% in Phase 3 IgAN trial interim analysis, supporting regulatory filings.
An excerpt from the original article.
Comments —
Loading comments…